BioPharmSignal logoBioPharmSignal

Biotech News

Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)

Jaguar Health (JAGX)Jaguar HealthConference / presentation

Company remains sharply focused on its ongoing global development program for crofelemer for rare IF diseases Near-term milestones for IF program buttressed by continuing groundbreaking results of study, which demonstrate reduction of parenteral support normalized to body weight of up to 48% in

Related news

JAGXJaguar Health2026-06-12 13:00 EST

Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure Diseases

JAGXJaguar Health2026-09-29 08:30 EST

Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting

SCYXSCYNEXIS2026-10-29 12:00 EST

SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference

HROWHarrow, Inc.2026-03-18 11:00 EST

Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting

VIRXViracta Therapeutics2024-09-05 15:32 EST

Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

SCYXSCYNEXIS2026-10-21 20:05 EST

SCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeek

HROWHarrow, Inc.2026-05-27 11:00 EST

Harrow to Present at William Blair’s 46th Annual Growth Stock Conference

IBRXImmunityBio2026-03-09 11:30 EST

ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data

IBRXImmunityBio2026-05-20 00:30 EST

ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027

ALZNAlzamend Neuro2026-08-18 12:00 EST

Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain

View all latest news

Jaguar Health

Plant-Derived Gastrointestinal Medicines Jaguar Health develops prescription medicines derived from plants for serious gastrointestinal disorders. Its Napo subsidiaries lead development and commercialization of crofelemer for rare intestinal-failure conditions. Crofelemer Mechanism Crofelemer is a plant-derived antisecretory medicine...

Recent company news

JAGXJaguar Health2026-11-06 21:15 EST

Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders

JAGXJaguar Health2026-11-02 14:00 EST

CSO of Napo Pharmaceuticals, a Jaguar Health Family Company, and Clinical Investigators Evaluating Crofelemer Conduct Panel Discussion at Pediatric Gastroenterology Conference in Dubai (UAE)

JAGXJaguar Health2026-10-21 13:00 EST

Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure (IF) in Third Rare Congenital Enteropathy Disorder

JAGXJaguar Health2026-10-14 20:15 EST

Jaguar Health Provides Update Regarding Special Stock Dividend

JAGXJaguar Health2026-10-14 13:00 EST

Positive Preliminary Results Presented at Annual American College of Gastroenterology Meeting for Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer

Stock data

Close
0.41 USD
Market cap
2.12M USD
Exchange
NASDAQ
Sector
Biopharma
Location
San Francisco, California